search
Back to results

Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients (RADIANCE)

Primary Purpose

Relapsing Multiple Sclerosis

Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Ozanimod
Placebo
Sponsored by
Celgene
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Relapsing Multiple Sclerosis

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Multiple sclerosis as diagnosed by the revised 2010 McDonald criteria
  • Expanded Disability Status Scale (EDSS) score between 0 and 5.0 at Baseline

Exclusion Criteria:

  • Secondary or primary progressive multiple sclerosis

Sites / Locations

  • Alta Bates Summit Medical Center
  • Neuro Pain Medical Center
  • University of California Davis Medical Center
  • The Neurological Institute PA
  • Neurology and Neuroscience Associates Inc.
  • The Polyclinic
  • Cliniques Universitaires St-Luc
  • Centre Hospitalier Chretien Clinique Saint Joseph
  • Clinique Saint-Pierre
  • University Multiprofile Hospital for Active Treatment Sv Ivan Rilski EAD
  • Sarajishvili Institute of Neurology
  • LTD MediClubGeorgia
  • Khechinashvili University Hospital
  • Evaggelismos General Hospital
  • 401 Military Hospital of Athens
  • Georgios Papanikolaou General Hospital of Thessaloniki
  • Vaszary Kolos Korhaz
  • Azienda Ospedaliero Universitaria Policlinico Vittorio Emanuele
  • Powiatowy Zespol Zakladow Opieki Zdrowotnej Szpital w Czeladzi
  • Regionalny Szpital Specjalistyczny im. dr Wladyslawa Bieganskiego
  • Novo-Med Zielinski i wsp. Sp.J.
  • NEURO- CARE Site Management Organization Gabriela Klodowska-Duda
  • NEURO MEDIC Janusz Zbrojkiewicz
  • RESMEDICA Spolka z o.o.
  • Centrum Kompleksowej Rehabilitacji Sp.z.o.o. Szpital Wielospecjalistyczny
  • Prof. dr med. Zbigniew Stelmasiak Specjalistyczny Gabinet Neurologiczny
  • Centrum Neurologii Krzysztof Selmaj
  • Wojewodzki Szpital Specjalistyczny
  • Neurologiczny NZOZ Centrum Leczenia SM Osrodek Badan Klinicznych Dr n med Hanka Hertmanowska
  • Niepubliczny Zaklad Opieki Zdrowotnej KENDRON
  • Niepubliczny Zaklad Opieki Zdrowotnej NEUROKARD Ilkowski i Partnerzy Spolka Partnerska Lekarzy
  • EUROMEDIS Sp. z.o.o.
  • Indywidualna Specjalistyczna Praktyka Lekarska Zbigniew Cebulski
  • Szpital Czerniakowski Samodzielny Publiczny Zaklad Opieki Zdrowotnej
  • Centralny Szpital Kliniczny MSWIA
  • Wojskowy Instytut Medyczny
  • Instytut Psychiatrii i Neurologii
  • Health Club Medical Center S.R.L.
  • Rehabilitation Clinical Hospital
  • Colentina Clinical Hospital
  • Timisoara Emergency County Clinical Hospital
  • Republican Clinical Hospital for Rehabilitation Treatment
  • Research Medical Complex Vashe Zdorovie
  • City Clinical Hospital 4
  • Clinical Center of Serbia
  • Clinical Hospital Centar Zvezdara
  • Military Medical Academy
  • Clinical Hospital Centre Zemun
  • Clinical Center Kragujevac
  • Hospital Donostia
  • Hospital Universitari i Politecnic La Fe de Valencia
  • Municipal Medical & Preventive Institution Chernigiv Regional Clinical Hospital
  • Municipal Institution Dnipropetrovsk Regional Clinical Hospital na I.I. Mechnykov
  • Regional Clinical Hospital
  • State Treatment and Prevention Institution Central Clinical Hospital of Ukrzaliznytsya
  • Municipal Institution of Kyiv Regional Council Kyiv Regional Clinical Hospital
  • Volyn Regional Clinical Hospital
  • Municipal Institution Vinnytsya Regional Psychoneurological Hospital na OI Yushchenko

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Placebo Comparator

Arm Label

Ozanimod 0.5 mg

Ozanimod 1 mg

Placebo

Arm Description

Participants received ozanimod 0.5 mg oral capsules daily for 24 weeks. Participants who completed the 24-week treatment period had the option to enter the blinded extension period and continue to receive ozanimod 0.5 mg weekly for another 96 weeks.

Participants received ozanimod 0.5 mg oral capsules daily for 24 weeks. Participants who completed the 24-week treatment period had the option to enter the blinded extension period and continue to receive ozanimod 1 mg weekly for another 96 weeks.

Participants received placebo to ozanimod oral capsules daily for 24 weeks. Participants who completed the 24-week treatment period had the option to enter the blinded extension period and were randomized to receive ozanimod 0.5 mg or 1 mg weekly for 96 weeks.

Outcomes

Primary Outcome Measures

Total Number of Gadolinium-Enhancing (GdE) Lesions Assessed on Brain Magnetic Resonance Imaging (MRI) From Week 12 to Week 24
The cumulative number of total GdE lesions on MRI from Week 12 to Week 24. MRI scans were assessed and scored by an independent MRI analysis center with no knowledge of treatment assignment or outcomes.

Secondary Outcome Measures

The Number of Gadolinium-Enhancing Lesions on Brain MRI Scan at Week 24
MRI scans were assessed and scored by an independent MRI analysis center with no knowledge of treatment assignment or outcomes.
The Total Number of New or Enlarging Hyperintense T2-Weighted Brain MRI Lesions From Week 12 to Week 24
The cumulative number of new or enlarging hyperintense T2-weighted brain MRI lesions from Week 12 to Week 24. MRI scans were assessed and scored by an independent MRI analysis center with no knowledge of treatment assignment or outcomes.
Adjusted Annualized Relapse Rate (ARR) at Week 24
A relapse was defined as new or worsening neurological symptoms attributable to MS and preceded by a relatively stable or improving neurological state for at least 30 days. Symptoms must have persisted for > 24 hours and not be attributable to confounding clinical factors. Relapses were confirmed when accompanied by objective neurological worsening based on examination by the blinded evaluator, consistent with an increase of ≥ 0.5 on the overall EDSS score relative to the most recent EDSS assessment, or 2 points on one of the functional system scale scores, or 1 point on ≥ two functional system scale scores. Relapse rate was calculated as the total number of confirmed relapses divided by the total number of days in the study * 365. ARR was based on a Poisson regression model, adjusted for region, relapses within 24 months before the study, and presence of gadolinium-enhancing lesions at Baseline.
Number of Participants With Treatment Emergent Adverse Events (TEAE) During the Placebo-Controlled Treatment Period
An adverse event (AE) is any untoward medical occurrence that does not necessarily have a causal relationship with the investigational product (IP), including an abnormal laboratory finding, symptom or disease temporally associated with the use of an IP whether or not considered related to the IP. Serious AEs were events that resulted in death, were life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability or incapacity, were congenital abnormalities/birth defects, or important medical events which may have required medical intervention to prevent one of the above outcomes. The investigator assessed the severity of AEs as mild, moderate, or severe, and the relationship of each AE to treatment as unrelated, unlikely, possible, probable, or related based on timing and other known factors such as clinical state, environment, or other therapies.
Number of Participants With Treatment Emergent Adverse Events (TEAE) During Ozanimod Exposure
AEs are reported from the start of the placebo-controlled period for participants originally assigned to ozanimod and from the start of the extension period for participants who switched to ozanimod after Week 24. Serious AEs were events that resulted in death, were life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability or incapacity, were congenital abnormalities/birth defects, or important medical events which may have required medical intervention to prevent one of the above outcomes. The investigator assessed the severity of AEs as mild, moderate, or severe, and the relationship of each AE to treatment based on timing and other known factors such as clinical state, environment, or other therapies.

Full Information

First Posted
June 22, 2012
Last Updated
January 25, 2021
Sponsor
Celgene
search

1. Study Identification

Unique Protocol Identification Number
NCT01628393
Brief Title
Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients
Acronym
RADIANCE
Official Title
A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients
Study Type
Interventional

2. Study Status

Record Verification Date
January 2021
Overall Recruitment Status
Completed
Study Start Date
September 18, 2012 (Actual)
Primary Completion Date
April 13, 2014 (Actual)
Study Completion Date
May 11, 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Celgene

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study is a two-part trial consisting of Part A (presented in this record) and Part B (see NCT02047734). The primary objective in Part A of this study was to demonstrate the superior efficacy of ozanimod compared to placebo by showing a reduction in the cumulative number of total gadolinium-enhancing (GdE) lesions from Week 12 to Week 24 in patients with relapsing multiple sclerosis (RMS).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Relapsing Multiple Sclerosis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
258 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Ozanimod 0.5 mg
Arm Type
Experimental
Arm Description
Participants received ozanimod 0.5 mg oral capsules daily for 24 weeks. Participants who completed the 24-week treatment period had the option to enter the blinded extension period and continue to receive ozanimod 0.5 mg weekly for another 96 weeks.
Arm Title
Ozanimod 1 mg
Arm Type
Experimental
Arm Description
Participants received ozanimod 0.5 mg oral capsules daily for 24 weeks. Participants who completed the 24-week treatment period had the option to enter the blinded extension period and continue to receive ozanimod 1 mg weekly for another 96 weeks.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Participants received placebo to ozanimod oral capsules daily for 24 weeks. Participants who completed the 24-week treatment period had the option to enter the blinded extension period and were randomized to receive ozanimod 0.5 mg or 1 mg weekly for 96 weeks.
Intervention Type
Drug
Intervention Name(s)
Ozanimod
Other Intervention Name(s)
RPC1063, Zeposia®
Intervention Description
Oral capsule taken once a day
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Oral capsule taken once a day
Primary Outcome Measure Information:
Title
Total Number of Gadolinium-Enhancing (GdE) Lesions Assessed on Brain Magnetic Resonance Imaging (MRI) From Week 12 to Week 24
Description
The cumulative number of total GdE lesions on MRI from Week 12 to Week 24. MRI scans were assessed and scored by an independent MRI analysis center with no knowledge of treatment assignment or outcomes.
Time Frame
From Week 12 to Week 24; MRI was performed at Weeks 12, 16, 20, and 24
Secondary Outcome Measure Information:
Title
The Number of Gadolinium-Enhancing Lesions on Brain MRI Scan at Week 24
Description
MRI scans were assessed and scored by an independent MRI analysis center with no knowledge of treatment assignment or outcomes.
Time Frame
Week 24
Title
The Total Number of New or Enlarging Hyperintense T2-Weighted Brain MRI Lesions From Week 12 to Week 24
Description
The cumulative number of new or enlarging hyperintense T2-weighted brain MRI lesions from Week 12 to Week 24. MRI scans were assessed and scored by an independent MRI analysis center with no knowledge of treatment assignment or outcomes.
Time Frame
Week 12 to Week 24; MRI was performed at Weeks 12, 16, 20, and 24
Title
Adjusted Annualized Relapse Rate (ARR) at Week 24
Description
A relapse was defined as new or worsening neurological symptoms attributable to MS and preceded by a relatively stable or improving neurological state for at least 30 days. Symptoms must have persisted for > 24 hours and not be attributable to confounding clinical factors. Relapses were confirmed when accompanied by objective neurological worsening based on examination by the blinded evaluator, consistent with an increase of ≥ 0.5 on the overall EDSS score relative to the most recent EDSS assessment, or 2 points on one of the functional system scale scores, or 1 point on ≥ two functional system scale scores. Relapse rate was calculated as the total number of confirmed relapses divided by the total number of days in the study * 365. ARR was based on a Poisson regression model, adjusted for region, relapses within 24 months before the study, and presence of gadolinium-enhancing lesions at Baseline.
Time Frame
Week 24
Title
Number of Participants With Treatment Emergent Adverse Events (TEAE) During the Placebo-Controlled Treatment Period
Description
An adverse event (AE) is any untoward medical occurrence that does not necessarily have a causal relationship with the investigational product (IP), including an abnormal laboratory finding, symptom or disease temporally associated with the use of an IP whether or not considered related to the IP. Serious AEs were events that resulted in death, were life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability or incapacity, were congenital abnormalities/birth defects, or important medical events which may have required medical intervention to prevent one of the above outcomes. The investigator assessed the severity of AEs as mild, moderate, or severe, and the relationship of each AE to treatment as unrelated, unlikely, possible, probable, or related based on timing and other known factors such as clinical state, environment, or other therapies.
Time Frame
From first dose of study drug up to Week 24, or up to 28 days after the last dose for participants who did not enter the extension period.
Title
Number of Participants With Treatment Emergent Adverse Events (TEAE) During Ozanimod Exposure
Description
AEs are reported from the start of the placebo-controlled period for participants originally assigned to ozanimod and from the start of the extension period for participants who switched to ozanimod after Week 24. Serious AEs were events that resulted in death, were life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability or incapacity, were congenital abnormalities/birth defects, or important medical events which may have required medical intervention to prevent one of the above outcomes. The investigator assessed the severity of AEs as mild, moderate, or severe, and the relationship of each AE to treatment based on timing and other known factors such as clinical state, environment, or other therapies.
Time Frame
From the first dose of ozanimod, either in the placebo-controlled or the blinded extension period, up to 4 weeks after the last dose; mean duration of exposure was 25.4, 30.9, 24.6, and 32.3 months in each treatment group respectively.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Multiple sclerosis as diagnosed by the revised 2010 McDonald criteria Expanded Disability Status Scale (EDSS) score between 0 and 5.0 at Baseline Exclusion Criteria: Secondary or primary progressive multiple sclerosis
Facility Information:
Facility Name
Alta Bates Summit Medical Center
City
Berkeley
State/Province
California
ZIP/Postal Code
94705
Country
United States
Facility Name
Neuro Pain Medical Center
City
Fresno
State/Province
California
ZIP/Postal Code
93710
Country
United States
Facility Name
University of California Davis Medical Center
City
Sacramento
State/Province
California
ZIP/Postal Code
95817
Country
United States
Facility Name
The Neurological Institute PA
City
Charlotte
State/Province
North Carolina
ZIP/Postal Code
28204
Country
United States
Facility Name
Neurology and Neuroscience Associates Inc.
City
Akron
State/Province
Ohio
ZIP/Postal Code
44320
Country
United States
Facility Name
The Polyclinic
City
Seattle
State/Province
Washington
ZIP/Postal Code
98104
Country
United States
Facility Name
Cliniques Universitaires St-Luc
City
Brussels
ZIP/Postal Code
1200
Country
Belgium
Facility Name
Centre Hospitalier Chretien Clinique Saint Joseph
City
Montegnee
ZIP/Postal Code
4420
Country
Belgium
Facility Name
Clinique Saint-Pierre
City
Ottignies
ZIP/Postal Code
1340
Country
Belgium
Facility Name
University Multiprofile Hospital for Active Treatment Sv Ivan Rilski EAD
City
Sofia
ZIP/Postal Code
1431
Country
Bulgaria
Facility Name
Sarajishvili Institute of Neurology
City
Tbilisi
ZIP/Postal Code
0112
Country
Georgia
Facility Name
LTD MediClubGeorgia
City
Tbilisi
ZIP/Postal Code
0160
Country
Georgia
Facility Name
Khechinashvili University Hospital
City
Tbilisi
ZIP/Postal Code
0179
Country
Georgia
Facility Name
Evaggelismos General Hospital
City
Athens
ZIP/Postal Code
10676
Country
Greece
Facility Name
401 Military Hospital of Athens
City
Athens
ZIP/Postal Code
11525
Country
Greece
Facility Name
Georgios Papanikolaou General Hospital of Thessaloniki
City
Thessaloniki
ZIP/Postal Code
57010
Country
Greece
Facility Name
Vaszary Kolos Korhaz
City
Esztergom
ZIP/Postal Code
2500
Country
Hungary
Facility Name
Azienda Ospedaliero Universitaria Policlinico Vittorio Emanuele
City
Cantania
ZIP/Postal Code
95123
Country
Italy
Facility Name
Powiatowy Zespol Zakladow Opieki Zdrowotnej Szpital w Czeladzi
City
Czeladz
ZIP/Postal Code
41-250
Country
Poland
Facility Name
Regionalny Szpital Specjalistyczny im. dr Wladyslawa Bieganskiego
City
Grudziadz
ZIP/Postal Code
86-300
Country
Poland
Facility Name
Novo-Med Zielinski i wsp. Sp.J.
City
Katowice
ZIP/Postal Code
40-650
Country
Poland
Facility Name
NEURO- CARE Site Management Organization Gabriela Klodowska-Duda
City
Katowice
ZIP/Postal Code
40-749
Country
Poland
Facility Name
NEURO MEDIC Janusz Zbrojkiewicz
City
Katowice
ZIP/Postal Code
40-752
Country
Poland
Facility Name
RESMEDICA Spolka z o.o.
City
Kielce
ZIP/Postal Code
25-726
Country
Poland
Facility Name
Centrum Kompleksowej Rehabilitacji Sp.z.o.o. Szpital Wielospecjalistyczny
City
Konstancin Jeziorna
ZIP/Postal Code
05-510
Country
Poland
Facility Name
Prof. dr med. Zbigniew Stelmasiak Specjalistyczny Gabinet Neurologiczny
City
Lublin
ZIP/Postal Code
20-718
Country
Poland
Facility Name
Centrum Neurologii Krzysztof Selmaj
City
Lódzkie
ZIP/Postal Code
90-324
Country
Poland
Facility Name
Wojewodzki Szpital Specjalistyczny
City
Olsztyn
ZIP/Postal Code
10-561
Country
Poland
Facility Name
Neurologiczny NZOZ Centrum Leczenia SM Osrodek Badan Klinicznych Dr n med Hanka Hertmanowska
City
Plewiska
ZIP/Postal Code
62-064
Country
Poland
Facility Name
Niepubliczny Zaklad Opieki Zdrowotnej KENDRON
City
Podlaskie
ZIP/Postal Code
15-402
Country
Poland
Facility Name
Niepubliczny Zaklad Opieki Zdrowotnej NEUROKARD Ilkowski i Partnerzy Spolka Partnerska Lekarzy
City
Poznan
ZIP/Postal Code
61-853
Country
Poland
Facility Name
EUROMEDIS Sp. z.o.o.
City
Szczecin
ZIP/Postal Code
70-111
Country
Poland
Facility Name
Indywidualna Specjalistyczna Praktyka Lekarska Zbigniew Cebulski
City
Warminsko-mazurskie
ZIP/Postal Code
10-443
Country
Poland
Facility Name
Szpital Czerniakowski Samodzielny Publiczny Zaklad Opieki Zdrowotnej
City
Warsaw
ZIP/Postal Code
00-739
Country
Poland
Facility Name
Centralny Szpital Kliniczny MSWIA
City
Warsaw
ZIP/Postal Code
02-507
Country
Poland
Facility Name
Wojskowy Instytut Medyczny
City
Warszawa
ZIP/Postal Code
00-909
Country
Poland
Facility Name
Instytut Psychiatrii i Neurologii
City
Warszawa
ZIP/Postal Code
02-957
Country
Poland
Facility Name
Health Club Medical Center S.R.L.
City
Campulung
ZIP/Postal Code
115100
Country
Romania
Facility Name
Rehabilitation Clinical Hospital
City
Cluj-Napoca
ZIP/Postal Code
400347
Country
Romania
Facility Name
Colentina Clinical Hospital
City
Napoca
ZIP/Postal Code
400001
Country
Romania
Facility Name
Timisoara Emergency County Clinical Hospital
City
Timisoara
ZIP/Postal Code
300736
Country
Romania
Facility Name
Republican Clinical Hospital for Rehabilitation Treatment
City
Kazan
ZIP/Postal Code
420021
Country
Russian Federation
Facility Name
Research Medical Complex Vashe Zdorovie
City
Kazan
ZIP/Postal Code
420097
Country
Russian Federation
Facility Name
City Clinical Hospital 4
City
Saransk
ZIP/Postal Code
430032
Country
Russian Federation
Facility Name
Clinical Center of Serbia
City
Belgrade
ZIP/Postal Code
11000
Country
Serbia
Facility Name
Clinical Hospital Centar Zvezdara
City
Belgrade
ZIP/Postal Code
11000
Country
Serbia
Facility Name
Military Medical Academy
City
Belgrade
ZIP/Postal Code
11000
Country
Serbia
Facility Name
Clinical Hospital Centre Zemun
City
Belgrade
ZIP/Postal Code
11080
Country
Serbia
Facility Name
Clinical Center Kragujevac
City
Kragujevac
ZIP/Postal Code
34000
Country
Serbia
Facility Name
Hospital Donostia
City
San Sebastian
ZIP/Postal Code
20014
Country
Spain
Facility Name
Hospital Universitari i Politecnic La Fe de Valencia
City
Valencia
ZIP/Postal Code
46026
Country
Spain
Facility Name
Municipal Medical & Preventive Institution Chernigiv Regional Clinical Hospital
City
Chernigiv
ZIP/Postal Code
14033
Country
Ukraine
Facility Name
Municipal Institution Dnipropetrovsk Regional Clinical Hospital na I.I. Mechnykov
City
Dnipropetrovsk
ZIP/Postal Code
49027
Country
Ukraine
Facility Name
Regional Clinical Hospital
City
Ivano Frankivsk
ZIP/Postal Code
76008
Country
Ukraine
Facility Name
State Treatment and Prevention Institution Central Clinical Hospital of Ukrzaliznytsya
City
Kharkiv
ZIP/Postal Code
61103
Country
Ukraine
Facility Name
Municipal Institution of Kyiv Regional Council Kyiv Regional Clinical Hospital
City
Kyiv
ZIP/Postal Code
04107
Country
Ukraine
Facility Name
Volyn Regional Clinical Hospital
City
Lutsk
ZIP/Postal Code
43024
Country
Ukraine
Facility Name
Municipal Institution Vinnytsya Regional Psychoneurological Hospital na OI Yushchenko
City
Vinnytsya
ZIP/Postal Code
21005
Country
Ukraine

12. IPD Sharing Statement

Citations:
PubMed Identifier
26879276
Citation
Cohen JA, Arnold DL, Comi G, Bar-Or A, Gujrathi S, Hartung JP, Cravets M, Olson A, Frohna PA, Selmaj KW; RADIANCE Study Group. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2016 Apr;15(4):373-81. doi: 10.1016/S1474-4422(16)00018-1. Epub 2016 Feb 12.
Results Reference
result
PubMed Identifier
30043658
Citation
Cohen JA, Comi G, Arnold DL, Bar-Or A, Selmaj KW, Steinman L, Havrdova EK, Cree BA, Montalban X, Hartung HP, Huang V, Frohna P, Skolnick BE, Kappos L; RADIANCE Trial Investigators. Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study. Mult Scler. 2019 Aug;25(9):1255-1262. doi: 10.1177/1352458518789884. Epub 2018 Jul 25.
Results Reference
result

Learn more about this trial

Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients

We'll reach out to this number within 24 hrs